Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.01 | -0.00 |
| FCF Yield | 14,037.03% | 6,793.94% | 4,753.72% | 4,428.09% |
| EV / EBITDA | 12.93 | 1.56 | 1.66 | 1.59 |
| Quality | ||||
| ROIC | 14.49% | 10.25% | 9.44% | 7.99% |
| Gross Margin | 56.80% | 76.24% | 78.04% | 78.57% |
| Cash Conversion Ratio | -1.70 | 1.72 | 2.06 | 2.31 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.52% | -1.00% | 2.78% | 21.06% |
| Free Cash Flow Growth | 10.20% | 5.88% | -21.57% | 14.55% |
| Safety | ||||
| Net Debt / EBITDA | 12.90 | 1.55 | 1.64 | 1.57 |
| Interest Coverage | 4.96 | 7.03 | 7.39 | 6.40 |
| Efficiency | ||||
| Inventory Turnover | 8.16 | 4.02 | 4.33 | 4.74 |
| Cash Conversion Cycle | 65.85 | 103.41 | 84.97 | 67.13 |